Who we are
Upon injury or infection, prokaryotic and/or eukaryotic cells release plethora of disorganized denatured molecules into tissue microenvironment.
Many of them are water-insoluble, that clog capillaries, incur damages of cellular membrane and disturb tissue homeostasis.
The water-insoluble molecules in living organisms need to be removed as soon as they appear in tissues.
If not, they cause deleterious inflammation.
Hydrophobicity : an ancient damage-associated molecular pattern that initiates innate immune responses SY Seong, P Matzinger - Nature Review Immunology, 2004
In the beginning, life on earth was created in the water.
The battle between water-soluble and insoluble substances began when the lives advanced to the land.
Water-insoluble molecules are the origin of foe.
The immune system has piggy-backed on the system devastating water-insoluble aggregates.
We study immunology and inflammation, taking biological solubility at the center of intricate immunological balance.
What we do
- New Approach to Inflammatory Diseases (Small Molecule)
- Based on deep understanding of DAMPs (Damage Associated Molecular Patterns)
- Targeting multi-modal, complex inflammatory diseases
- Developing immune modulating molecules with strong efficacy and excellent safety profiles
- Next Generation NanoMAb® Technology
- Based on a wide array of nanobody libraries from immunized camelid
- Focusing on new antigen targets
- Developing nanobody-based cancer therapeutics with high affinity and low immunogenicity
- From bispecific nanobodies to genetically conjugated Nanotoxin®
- High-throughput cell line development
- Targeted integration into hot-spot chromatin structure
- Multi-targeting with stable protein structure
- Seoul National University, College of Medicine, M.D., Ph.D.
- Professor, Chair of Microbiology and Immunology, Seoul National University, College of Medicine
- Director(former), Wide River Institute of Immunology, Seoul National University
- Chief Editor, World Journal of Immunology
Major publications as a corresponding author
‘Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune response’ (Nature Reviews Immunology, 2004)
‘Multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy’ (Nature Nanotechnology, 2011)
- University of Tokyo, College of Pharmacy, Ph.D.
- Ewha Woman’s University, College of Pharmacy, MSc.
- Managing Director of R&D Center, Sinsin Pharmaceutical Co., Ltd.
- Director, new drug development, Reyon Phamaceutical Co., Ltd.
- General manager, regulatory affairs and drug development, Bukwang Pharmaceutical Co., Ltd.
- Senior manager, drug development, Dongwha Pharmaceutical Co., Ltd.
- Principal research scientist, Mogam Biotechnology Research Institute
- University of Michigan, Ann Arbor, MBA
- Yonsei University, BA
- CEO, SK Plasma Co., Ltd.
- VP, business development/strategic planning/licensing, SK Chemicals Life Science
- CEO, SK Eurochem
- Senior consultant, Ernst & Young Consulting Co.
- Manager, international business, Kolon International Co.
- Seoul National University, Interdisciplinary Program of Agricultural Biotechnology, Ph.D.
- Seoul National University, College of Agricultural Chemistry, MSc.
- Senior manager, cell line engineering/R&D planning, GC Pharma
- Adjunct professor, Department of Biotechnology, The Catholic University of Korea
- Chief researcher, rare disease/protein engineering, Mogam Institute for Biomedical Research
- Seoul National University, College of Pharmacy, Ph.D.
- Kangwon National University, College of Pharmacy, MSc.
- Senior manager, technology transfer & manufacturing oversight, CJ Healthcare
- Head of drug evaluation center, CJ Cheiljedang
- Senior manager, clinical development/R&D strategy, YUHAN